US · Healthcare · Biotechnology
EPS came in at -0.80 against a street estimate of -0.63 — a miss of 27.0%.
Analysts rate Hemab Therapeutics Holdings, Inc. Common Stock a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $61.20.
| Fund | Stake |
|---|---|
| RA Capital Management, LLC | 16.72% |
| Novo A/S | 8.95% |
| FMR Inc | 7.92% |
| Capital Research & Mgmt Co - Division 3 | 7.72% |
| Deep Track Capital, LP | 7.71% |
| Siren, L.L.C. | 4.47% |
| venBio Select Advisor LLC | 4.12% |
| Bain Capital Life Sciences Investors, LLC | 3.53% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 HEMAB THERAPEUTICS HOLDINGS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company: Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG) • Filing Date: Septembe | 2026-09-24 |
| Quarterly report · Q2 2026 HEMAB THERAPEUTICS HOLDINGS, INC. — 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash position: $237.4 million cash and cash equivalents as of June 30, | 2026-08-11 |
| Results announced · Q3 2026 HEMAB THERAPEUTICS – Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash position: $457.5 million as of June 30, 2026 (up from $163.5 million on March | 2026-08-11 |
| Quarterly report · Q1 2026 HEMAB THERAPEUTICS HOLDINGS, INC. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash Position: $49.9 million in cash and cash equivalents as of March 31 | 2026-05-21 |
| Results announced · Q2 2026 HEMAB THERAPEUTICS Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Net loss of $22.7 million for Q1 2026 ($23.98 per share), up from $15.3 mill | 2026-05-21 |
| Board / officer change · Q2 2026 HEMAB THERAPEUTICS HOLDINGS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Company: Hemab Therapeutics Holdings, Inc. (ticker: COAG, Nasdaq Global Select Ma | 2026-05-11 |
| Charter / bylaws change · Q2 2026 HEMAB THERAPEUTICS HOLDINGS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Company completed initial public offering (IPO) on May 4, 2026 • Issued 19,262,50 | 2026-05-04 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Hemab Therapeutics Holdings, Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.